# US 2025/0145702 A1 · Egfl6 specific monoclonal antibodies and methods of their use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0145702 A1
- Document ID: US20250145702A1
- Status: Published application
- Kind: A1
- Application number: 18/920,268
- Filed: 2024-10-18
- Published: 2025-05-08
- Earliest claimed: 2016-02-05
- Assignees: Board of Regents, The University of Texas System
- Applicants: The Board of Regents of the University of Texas System
- Inventors: Ningyan ZHANG; Zhiqiang AN; Anil K. SOOD
- Web page: https://patentgrep.com/patent/US20250145702A1

## CPC

- C07K 16/22: against growth factors {; against growth regulators}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61P 35/00: Antineoplastic agents
- C12N 15/1136: {against growth factors, growth regulators, cytokines, lymphokines or hormones}
- G01N 33/57545: of the ovaries
- A61K 2039/505: {comprising antibodies}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C12N 2310/14: interfering nucleic acids [NA]
- G01N 2333/485: Epidermal growth factor [EGF] (urogastrone)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Isolated or recombinant anti-EGFL6 monoclonal antibodies are provided. In some cases, antibodies of the embodiments can be used for the detection, diagnosis and/or therapeutic treatment of human diseases, such as cancer.

## Claims

### Claim at position 1

1-55. (canceled)

### Claim 56

One or more polynucleotide molecules encoding an antibody or antigen-binding fragment thereof that specifically binds to epidermal growth factor-like domain-containing protein 6 (EGFL6) and comprises:
(a) a VH CDR1 identical to SEQ ID NO: 64;
(b) a VH CDR2 identical to SEQ ID NO:65;
(c) a VH CDR3 identical to SEQ ID NO: 66;
(d) a VL CDR1 identical to SEQ ID NO: 126;
(e) a VL CDR2 identical to SEQ ID NO: 127; and
(f) a VL CDR3 identical to SEQ ID NO: 128.

### Claim 57 (depends on 56)

The one or more polynucleotide molecules of claim 56, wherein the antibody or antigen binding fragment thereof comprises a VH domain at least about 80% identical to SEQ ID NO: 177; and a VL domain at least about 80% identical to SEQ ID NO: 178.

### Claim 58 (depends on 56)

The one or more polynucleotide molecules of claim 56, wherein the antibody or antigen-binding fragment is an IgG.

### Claim 59 (depends on 56)

The one or more polynucleotide molecules of claim 56, wherein the antibody or antigen-binding fragment is an Fab′, an F(ab′)2, an F(ab′)3, a monovalent scFv, or a bivalent scFv.

### Claim 60 (depends on 56)

The one or more polynucleotide molecules of claim 56, wherein the antibody or antigen binding fragment thereof comprises a VH domain identical to SEQ ID NO: 177 and a VL domain identical to SEQ ID NO: 178.

### Claim 61 (depends on 56)

The one or more polynucleotide molecules of claim 56, wherein the one or more polynucleotide molecules are comprised within an expression vector.

### Claim 62 (depends on 56)

A cell comprising the one or more polynucleotide molecules of claim 56.

### Claim 63 (depends on 62)

The cell of claim 62, wherein the cell is selected from the group consisting of a mammalian cell, a yeast cell, a bacterial cell, and an insect cell.

### Claim 64 (depends on 56)

A method of manufacturing an antibody or an antigen-binding fragment thereof, the method comprising expressing the one or more polynucleotide molecules of claim 56 in a cell and purifying the antibody from the cell.
